Adel Zaatar

655 total citations · 1 hit paper
9 papers, 476 citations indexed

About

Adel Zaatar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Adel Zaatar has authored 9 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Adel Zaatar's work include Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Genomics and Diagnostics (2 papers). Adel Zaatar is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Genomics and Diagnostics (2 papers). Adel Zaatar collaborates with scholars based in Australia, Singapore and Malaysia. Adel Zaatar's co-authors include Vera Hirsh, Val Gebski, Chris Brown, James Chih‐Hsin Yang, Chee Khoon Lee, Chun‐Ming Tsai, D. Chu, Akira Inoue, Siow Ming Lee and Joseph S. K. Au and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

Adel Zaatar

9 papers receiving 471 citations

Hit Papers

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on... 2013 2026 2017 2021 2013 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adel Zaatar Australia 5 376 328 126 105 30 9 476
Kevin Jao Canada 10 337 0.9× 293 0.9× 145 1.2× 142 1.4× 24 0.8× 23 476
Stefania Kinspergher Italy 12 318 0.8× 227 0.7× 97 0.8× 112 1.1× 34 1.1× 36 428
Changli Wang China 13 450 1.2× 346 1.1× 89 0.7× 114 1.1× 37 1.2× 29 522
Feiyu Niu China 12 314 0.8× 266 0.8× 175 1.4× 130 1.2× 54 1.8× 25 513
M.R. García Campelo Spain 9 301 0.8× 284 0.9× 119 0.9× 90 0.9× 19 0.6× 35 387
J. M. Sanchez Spain 9 315 0.8× 293 0.9× 211 1.7× 138 1.3× 20 0.7× 15 499
Sebastian Michels Germany 9 227 0.6× 200 0.6× 131 1.0× 85 0.8× 24 0.8× 53 357
Eamon M. Berge United States 8 425 1.1× 303 0.9× 231 1.8× 141 1.3× 35 1.2× 14 540
She-Juan An China 6 362 1.0× 281 0.9× 138 1.1× 139 1.3× 27 0.9× 7 453
Janice J.N. Li Canada 9 219 0.6× 178 0.5× 114 0.9× 132 1.3× 23 0.8× 16 335

Countries citing papers authored by Adel Zaatar

Since Specialization
Citations

This map shows the geographic impact of Adel Zaatar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adel Zaatar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adel Zaatar more than expected).

Fields of papers citing papers by Adel Zaatar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adel Zaatar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adel Zaatar. The network helps show where Adel Zaatar may publish in the future.

Co-authorship network of co-authors of Adel Zaatar

This figure shows the co-authorship network connecting the top 25 collaborators of Adel Zaatar. A scholar is included among the top collaborators of Adel Zaatar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adel Zaatar. Adel Zaatar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Liam, Chong Kin, Chee-Shee Chai, Gwo Fuang Ho, et al.. (2019). P2.14-47 Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S848–S848. 1 indexed citations
2.
Ho, Gwo Fuang, Chee-Shee Chai, Adlinda Alip, et al.. (2019). Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 19(1). 896–896. 36 indexed citations
4.
Yusof, Mastura Md, et al.. (2016). Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. Asian Pacific Journal of Cancer Prevention. 17(3). 973–978. 6 indexed citations
6.
Cheng, Ann‐Lii, Gerardo Cornelio, Lin Shen, et al.. (2013). First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study. Annals of Oncology. 24. iv34–iv35. 4 indexed citations
7.
Lee, Chee Khoon, Chris Brown, Richard J. Gralla, et al.. (2013). Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. JNCI Journal of the National Cancer Institute. 105(9). 595–605. 383 indexed citations breakdown →
8.
Zaatar, Adel, et al.. (2012). Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma. Journal of Experimental & Clinical Cancer Research. 31(1). 76–76. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026